vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics

vTv Therapeutics Inc. - (VTVT): $23.53

0.27 (-1.13%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add VTVT to Watchlist
Sign Up

VTVT Price/Volume Stats

Current price $23.53 52-week high $39.60
Prev. close $23.80 52-week low $7.38
Day low $22.81 Volume 15,145
Day high $25.07 Avg. volume 77,779
50-day MA $13.36 Dividend yield N/A
200-day MA $17.98 Market Cap 70.83M

VTVT Stock Price Chart Interactive Chart >

VTVT Stock Summary

  • With a price/sales ratio of 3,003.7, VTV THERAPEUTICS INC has a higher such ratio than 99.73% of stocks in our set.
  • As for revenue growth, note that VTVT's revenue has grown -99.55% over the past 12 months; that beats the revenue growth of merely 0.74% of US companies in our set.
  • In terms of volatility of its share price, VTVT is more volatile than 99.53% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VTV THERAPEUTICS INC are BNOX, OGEN, ONTX, VYNE, and LOOP.
  • VTVT's SEC filings can be seen here. And to visit VTV THERAPEUTICS INC's official web site, go to www.vtvtherapeutics.com.

VTVT Valuation Summary

  • VTVT's price/earnings ratio is -1.4; this is 104.8% lower than that of the median Healthcare stock.
  • Over the past 102 months, VTVT's price/sales ratio has gone up 3105.2.

Below are key valuation metrics over time for VTVT.

Stock Date P/S P/B P/E EV/EBIT
VTVT 2023-12-29 3344.4 -1.2 -1.4 -1.1
VTVT 2023-12-28 2666.7 -1.0 -1.1 -0.8
VTVT 2023-12-27 2688.9 -1.0 -1.1 -0.8
VTVT 2023-12-26 2500.0 -0.9 -1.0 -0.7
VTVT 2023-12-22 2611.1 -0.9 -1.1 -0.7
VTVT 2023-12-21 2611.1 -0.9 -1.1 -0.7

VTVT Growth Metrics

    Its year over year cash and equivalents growth rate is now at 43.66%.
  • Its 5 year cash and equivalents growth rate is now at -93.56%.
  • Its 3 year price growth rate is now at -70.87%.
Over the past 15 months, VTVT's revenue has gone down $5,384,000.

The table below shows VTVT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.018 -15.559 -21.47
2022-06-30 5.018 -10.326 -18.296
2022-03-31 5.018 -15.03 -15.753
2021-12-31 4.005 -19.308 -12.987
2021-09-30 10.395 -15.103 -4.81
2021-06-30 7.402 -16.943 -5.256

VTVT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTVT has a Quality Grade of D, ranking ahead of 9.32% of graded US stocks.
  • VTVT's asset turnover comes in at 0.491 -- ranking 86th of 682 Pharmaceutical Products stocks.
  • TVTX, ASRT, and AMPH are the stocks whose asset turnover ratios are most correlated with VTVT.

The table below shows VTVT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.491 1 -1.393
2021-03-31 0.601 1 -5.046
2020-12-31 0.644 1 196.403
2020-09-30 0.003 1 20.944
2020-06-30 0.003 1 38.942
2020-03-31 0.212 1 -34.603

VTVT Price Target

For more insight on analysts targets of VTVT, see our VTVT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.75 Average Broker Recommendation 1.5 (Moderate Buy)

vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about VTV THERAPEUTICS INC that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on

Yahoo | November 9, 2023

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15,

Yahoo | November 8, 2023

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutic

Yahoo | November 2, 2023

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for to

Yahoo | November 1, 2023

One vTv Therapeutics Insider Raised Their Stake In The Previous Year

From what we can see, insiders were net buyers in vTv Therapeutics Inc.'s ( NASDAQ:VTVT ) during the past 12 months...

Yahoo | October 19, 2023

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo 176.83%
3-mo 104.61%
6-mo 23.06%
1-year -25.54%
3-year -77.02%
5-year -65.60%
YTD 104.61%
2023 -56.62%
2022 -33.39%
2021 -46.51%
2020 9.41%
2019 -35.85%

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!